

**Supplementary Table 4**– Age eligibility requirements and sub-groups assessed for clinical trials with mortality outcomes

| <b>Clinical trial name (Clinical trial ID)</b>                                                                                         | <b>Ages eligible for azithromycin in study</b> | <b>Childhood mortality age groups analyzed</b>                         |
|----------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------|------------------------------------------------------------------------|
| Trachoma Amelioration in Northern Amhara (TANA; NCT00322972)                                                                           | 12 months and older                            | 1–5 years<br>6–10 years<br>Total childhood mortality (≥ 1 year of age) |
| Tripartite International Research for the Elimination of Trachoma (NCT01202331)                                                        | 6 months and older                             | 6 months to 5 years<br>6–10 years<br>> 10 years                        |
| Mortality Reduction After Oral Azithromycin: Mortality Study (NCT02047981)                                                             | 1–60 months                                    | 1–5 months<br>6–11 months<br>12–23 months<br>24–59 months              |
| Mortality Reduction After Oral Azithromycin Contingency: Mortality Study (NCT03338244)                                                 | 1–60 months                                    | 1–5 months<br>6–11 months<br>12–23 months<br>24–59 months              |
| Community Health Azithromycin Trial in Burkina Faso (NCT03676764)                                                                      | 1–59 months                                    | 4–12 weeks<br>1–59 months                                              |
| Azithromycin for Child Survival in Niger: Mortality and Resistance Trial (NCT04224987)                                                 | 1–59 months                                    | 1–11 months<br>12–59 months                                            |
| Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in Mali (NCT04424511) | 1–11 months                                    | 1–5 months<br>6–11 months                                              |
| Infant Mortality Reduction by the Mass Administration of Azithromycin (NCT04716712)                                                    | 1–11 months                                    | 1–11 months                                                            |
| Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR, NCT05288023)                                                     | 1–11 months                                    | Not listed                                                             |